Synapse

← Deepak L. Bhatt

Papers by Deepak L. Bhatt

Page 10 · newest first

  1. Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial InfarctionENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2022
  2. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of AlirocumabCirculation · 2022
  3. Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover studyJournal of Thrombosis and Thrombolysis · 2022
  4. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial InfarctionCirculation · 2022
  5. Polypill Strategy in Secondary Cardiovascular PreventionNew England Journal of Medicine · 2022
  6. The Relationship between Rate and Volume of Intravenous Fluid Administration and Kidney Outcomes after AngiographyClinical Journal of the American Society of Nephrology · 2022
  7. The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trialEuropean Heart Journal - Quality of Care and Clinical Outcomes · 2022
  8. Radiocephalic Arteriovenous Fistula Patency and UseAnnals of Surgery Open · 2022
  9. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 TrialDiabetes Care · 2022
  10. Trends in Lipid Concentrations and Lipid Control Among US Adults, 2007-2018JAMA · 2022
  11. Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromesJournal of clinical lipidology · 2022
  12. Comparison of 6-Month Outcomes of Endovascular vs Surgical Revascularization for Patients With Critical Limb IschemiaJAMA Network Open · 2022
  13. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smokingEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2022
  14. Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based studyEuropean Heart Journal Acute Cardiovascular Care · 2022
  15. Prevalence and Prognostic Implications of Reduced Left Ventricular Ejection Fraction Among Patients with STEMI in IndiaESC Heart Failure · 2022
  16. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trialAnnals of the Rheumatic Diseases · 2022
  17. Comparison of Unguided De-Escalation Versus Guided Selection of Dual Antiplatelet Therapy After Acute Coronary Syndrome: A Systematic Review and Network Meta-AnalysisCirculation Cardiovascular Interventions · 2022
  18. Left-sided Valvular Heart Disease and Survival in Out-of-Hospital Cardiac Arrest: A Nationwide Registry-Based Study2022
  19. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker SubstudyCirculation · 2022
  20. Analysis of Prescriptions for Dual Antiplatelet Therapy After Acute Ischemic StrokeJAMA Network Open · 2022
  21. A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial.2022
  22. Prognostic significance of obstructive coronary artery disease in patients admitted with acute decompensated heart failure: the ARIC study community surveillanceEuropean Journal of Heart Failure · 2022
  23. Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidenceDiabetes Obesity and Metabolism · 2022
  24. Preventive cardiology advances in the 2021 AHA/ACC chest pain guidelineAmerican Journal of Preventive Cardiology · 2022
  25. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal diseaseEuropean Heart Journal · 2022
  26. Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumabEuropean Journal of Preventive Cardiology · 2022
  27. Left-Sided Degenerative Valvular Heart Disease in Type 1 and Type 2 DiabetesCirculation · 2022
  28. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-ITJournal of clinical lipidology · 2022
  29. Efficacy and Safety Considerations With Dose-Reduced Direct Oral AnticoagulantsJAMA Cardiology · 2022
  30. Cangrelor Use Patterns and Transition to Oral P2Y ₁₂ Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO RegistryJournal of the American Heart Association · 2022
  31. Same‐Day Discharge After Transcatheter Aortic Valve Implantation: Insights from the Nationwide Readmission Database 2015 to 2019Journal of the American Heart Association · 2022
  32. Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMESCanadian Journal of Cardiology · 2022
  33. A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomesProstaglandins Leukotrienes and Essential Fatty Acids · 2022
  34. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trialENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2022
  35. Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trialCatheterization and Cardiovascular Interventions · 2022
  36. Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial InfarctionJournal of the American College of Cardiology · 2022
  37. Association of Influenza Vaccination With Cardiovascular RiskJAMA Network Open · 2022
  38. Cost–effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trialEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2022
  39. The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent EthylAmerican Journal of Preventive Cardiology · 2022
  40. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial InfarctionJournal of the American College of Cardiology · 2022
  41. The collateral damage of COVID-19 to cardiovascular services: a meta-analysisEuropean Heart Journal · 2022
  42. Perioperative management of P2Y12 inhibitors in patients undergoing cardiac surgery within 1 year of PCIEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2022
  43. Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trialEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2022
  44. Evaluation of Evidence-Based Dual Antiplatelet Therapy for Secondary Prevention in US Patients With Acute Ischemic StrokeJAMA Internal Medicine · 2022
  45. Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES TrialThe American Journal of Medicine · 2022
  46. Optimizing Foundational Therapies in Patients With HFrEFJACC Basic to Translational Science · 2022
  47. P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trialsEuropean Heart Journal Open · 2022
  48. Diagnosis and Treatment of Acute Coronary SyndromesJAMA · 2022
  49. Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin TreatmentJAMA Network Open · 2022
  50. Seasonal Variation of Atrial Fibrillation Admission and Quality of Care in the United StatesJournal of the American Heart Association · 2022